Sonoma Biotherapeutics lands $40 mn Series A
South San Francisco and Seattle-based Sonoma Biotherapeutics, a developer of regulatory T cell therapies for autoimmune and degenerative diseases, has raised $40 million in Series A financing.
South San Francisco and Seattle-based Sonoma Biotherapeutics, a developer of regulatory T cell therapies for autoimmune and degenerative diseases, has raised $40 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination
